Successful Treatment of a Patient with NSCLC Carrying Uncommon Compound L861Q/G719X Epidermal Growth Factor Receptor Mutations Using Afatinib

Overview

Journal Respir Med Case Rep

Date 2025 Jan 17

PMID 39822333

Authors

Zihan Zhou

Jie Huang

Ming Ding

Jing Huang

Ting Wu

Qun Wang

Shuhua Han

Yuan Lu

Affiliations

Soon will be listed here.

Abstract

The availability of targeted therapies for molecular aberrations have substantially improved the outcomes of advanced non-small-cell lung cancer (NSCLC) patients harboring sensitive mutations. However, patients harboring uncommon epidermal growth factor receptor (EGFR) mutations such as G719X and L861Q often resulted in a lack of response to the first and third generation of EGFR TKIs. In this study, we reported a 64-year-old female patient, who initially presented with symptoms of pneumonia and showed positive response to anti-infection treatment, eventually diagnosed with stage Ⅳ lung adenocarcinoma (LUAD) harboring a rare EGFR G719X and L861Q compound mutations. The patient received 40 mg/day of afatinib and experienced no severe adverse events. As a result, partial response (PR) was observed based on CT scan and a progression free survival of 24 month was achieved. Her follow-up is still ongoing. The results of the present case support the effectiveness and safety of afatinib in LUAD patients carrying EGFR G719X and L861Q compound mutations.

References

Kohsaka S, Nagano M, Ueno T, Suehara Y, Hayashi T, Shimada N . A method of high-throughput functional evaluation of gene variants of unknown significance in cancer. Sci Transl Med. 2017; 9(416). DOI: 10.1126/scitranslmed.aan6566. View

Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C . EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. Clin Cancer Res. 2015; 21(23):5305-13. DOI: 10.1158/1078-0432.CCR-15-1046. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Klughammer B, Brugger W, Cappuzzo F, Ciuleanu T, Mok T, Reck M . Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations. J Thorac Oncol. 2016; 11(4):545-55. DOI: 10.1016/j.jtho.2015.12.107. View

Yang J, Sequist L, Geater S, Tsai C, Mok T, Schuler M . Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015; 16(7):830-8. DOI: 10.1016/S1470-2045(15)00026-1. View

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C . Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361(10):958-67. DOI: 10.1056/NEJMoa0904554. View

Gristina V, Malapelle U, Galvano A, Pisapia P, Pepe F, Rolfo C . The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal. Cancer Treat Rev. 2020; 85:101994. DOI: 10.1016/j.ctrv.2020.101994. View

Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N . UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN). J Thorac Oncol. 2022; 18(2):169-180. DOI: 10.1016/j.jtho.2022.10.004. View

John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn M . Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol. 2021; 76:102080. DOI: 10.1016/j.canep.2021.102080. View

10.

Schuler M, Wu Y, Hirsh V, OByrne K, Yamamoto N, Mok T . First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016; 11(3):380-90. DOI: 10.1016/j.jtho.2015.11.014. View

11.

Wecker H, Waller C . Afatinib. Recent Results Cancer Res. 2018; 211:199-215. DOI: 10.1007/978-3-319-91442-8_14. View

12.

Russo A, Franchina T, Ricciardi G, Battaglia A, Picciotto M, Adamo V . Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario. Int J Mol Sci. 2019; 20(6). PMC: 6470640. DOI: 10.3390/ijms20061431. View

13.

Yang J, Schuler M, Popat S, Miura S, Heeke S, Park K . Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020; 15(5):803-815. DOI: 10.1016/j.jtho.2019.12.126. View

14.

Sato H, Offin M, Kubota D, Yu H, Wilhelm C, Toyooka S . Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. J Thorac Oncol. 2020; 16(1):113-126. PMC: 7775889. DOI: 10.1016/j.jtho.2020.09.019. View

15.

Shen Y, Tseng G, Tu C, Chen W, Liao W, Chen W . Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations. Lung Cancer. 2017; 110:56-62. DOI: 10.1016/j.lungcan.2017.06.007. View

16.

Park K, Tan E, OByrne K, Zhang L, Boyer M, Mok T . Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016; 17(5):577-89. DOI: 10.1016/S1470-2045(16)30033-X. View

17.

Hoffknecht P, Tufman A, Wehler T, Pelzer T, Wiewrodt R, Schutz M . Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease. J Thorac Oncol. 2014; 10(1):156-63. PMC: 4276567. DOI: 10.1097/JTO.0000000000000380. View

18.

. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511(7511):543-50. PMC: 4231481. DOI: 10.1038/nature13385. View

19.

Ma C, Zhang J, Tang D, Ye X, Li J, Mu N . Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon Mutations. Front Oncol. 2020; 10:224. PMC: 7066117. DOI: 10.3389/fonc.2020.00224. View

20.

Reungwetwattana T, Nakagawa K, Cho B, Cobo M, Cho E, Bertolini A . CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; :JCO2018783118. DOI: 10.1200/JCO.2018.78.3118. View